Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apyx Medical (NASDAQ:APYX) said management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will take part in a fireside chat at 8:25am ET and hold investor meetings throughout the day.
The fireside chat will be available via live webcast, with a replay posted in the Events section of Apyx Medical’s Investor Relations website.
Details
News Market Reaction – APYX
On Feb 18, the day this news came out, APYX closed 2.08% above the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Conference date
- March 11, 2026
- Citizens Life Sciences Conference participation
- Fireside chat time
- 8:25am ET
- Scheduled time for management fireside chat
- Supporting clinical documents
- More than 90
- Clinical documents supporting Renuvion and J-Plasma effectiveness
- Current share price
- $3.84
- Price before conference participation news
- 52-week high
- $4.50
- Upper end of 52-week trading range
- 52-week low
- $0.7554
- Lower end of 52-week trading range
- Price vs 52-week low
- 408.34%
- Price appreciation from 52-week low to $3.84
- Market capitalization
- $152,630,194
- Equity value prior to conference news
Historical Context
-
Management participation at BTIG MedTech and related conference visibility.
-
Strong Q4 and 2025 revenue growth led by Surgical Aesthetics segment.
-
MFDS approval and launch of Apyx One for cosmetic procedures in South Korea.
-
Pricing of $10M common stock offering at $3.62 per share under shelf.
-
Announcement of proposed public offering from existing S-3 registration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
helium plasma platform technology medical
body contouring system medical
electrosurgical medical
oem agreements financial
fda-cleared regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL.
Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Wednesday, March 11, 2026, at 8:25am ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast here, and a replay will be available on the Events section of Apyx Medical’s Investor Relations website.
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.